AbbVie is one of America's most prominent biopharmaceutical companies, spun out of Abbott Laboratories in 2013 and built around a commercial drug portfolio of considerable scale and reach. Listed on the NYSE under the ticker ABBV, the company is perhaps best known as the maker of Humira, for many years the world's best-selling prescription medicine, though its strategic priority in recent years has been diversifying beyond Humira as biosimilar competition has eroded that franchise.
The diversification effort has been substantial. AbbVie's acquisitions of Allergan and a series of oncology and immunology assets have broadened the pipeline meaningfully, with Skyrizi and Rinvoq emerging as the next generation of growth drivers. For traders, AbbVie is an interesting combination of defensive pharmaceutical income: the company has a strong dividend track record and binary event risk around clinical trial outcomes and regulatory decisions that can move the share price sharply in either direction.
Please note this is marketing communication, not recommendation or advice.
contas de clientes
A FxPro oferece aos clientes seus serviços de negociação on-line desde 1999, atendendo atualmente 173 países no mundo todo.
Prémios
A FxPro recebe constantemente reconhecimento na indústria, tendo vencido mais de 145 prêmios internacionais até o momento pela qualidade de seus serviços.
atendimento ao Cliente
Nossa equipe exclusiva de atendimento multilíngue trabalha 24 horas por dia para oferecer um nível excepcional de suporte.
regulamentos da indústria
A FxPro opera sob rigorosa supervisão regulatória em diversas jurisdições, incluindo autorização da FCA no Reino Unido — um dos reguladores financeiros mais confiáveis do mundo.
